Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Adverum Biotechnologies, Inc. (ADVM) had Normalized Pre-Tax Income of $-130.93M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$1.00M |
|
$-130.93M |
|
-- |
|
$1.00M |
|
$140.16M |
|
$-139.16M |
|
$8.23M |
|
$-130.93M |
|
|
Normalized Pre-Tax Income |
$-130.93M |
$-130.93M |
|
$-130.93M |
|
$-130.93M |
|
$-130.93M |
|
$-139.16M |
|
$-137.41M |
|
19.78M |
|
19.78M |
|
$-6.62 |
|
$-6.62 |
|
| Balance Sheet Financials | |
$131.30M |
|
$11.61M |
|
$48.54M |
|
$179.84M |
|
$22.90M |
|
-- |
|
$86.23M |
|
$109.13M |
|
$70.71M |
|
$70.71M |
|
$70.71M |
|
20.85M |
|
| Cash Flow Statement Financials | |
$-92.46M |
|
$-41.89M |
|
$120.00M |
|
$76.98M |
|
$62.63M |
|
$-14.35M |
|
$14.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-13915.90% |
|
-13915.90% |
|
-13741.30% |
|
-13092.70% |
|
-13092.70% |
|
$-92.85M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-185.15% |
|
-185.15% |
|
-72.80% |
|
-185.15% |
|
$3.39 |
|
$-4.69 |
|
$-4.67 |
|